Germline melanoma susceptibility and prognostic genes: A review of the literature

Journal of the American Academy of Dermatology

Volumn 67, Issue 5, 2012, Pages 1055-1067

  Ward, Katherine A ^a   Lazovich, Deann ^b   Hordinsky, Maria K ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cutaneous malignant melanoma; DNA repair; Genetic susceptibility; Germline; Immune responses; Metabolism; Nevus counts; Pigmentation; Prognosis; Vitamin D receptor

Indexed keywords

CALCITRIOL RECEPTOR;

GENETIC PREDISPOSITION; GENETICS; HUMAN; MELANOMA; MUTATION; PENETRANCE; PHYSIOLOGY; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TUMOR; TUMOR SUPPRESSOR GENE;

GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MELANOMA; PENETRANCE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, CALCITRIOL; SKIN NEOPLASMS;

EID: 84872679543     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.02.042     Document Type: Review

References (138)

1. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22:3053-62
2. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK42 binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9
3. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998;7:209-16
4. Hayward N. New developments in melanoma genetics. Curr Oncol Rep 2000;2:300-6
5. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009;41:920-8
6. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005;41:28-44
7. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001;2:25-31
8. Mocellin S, Verdi D, Nitti D. DNA repair gene polymorphisms and risk of cutaneous melanoma: A systematic review and meta-analysis. Carcinogenesis 2009;30:1735-43
9. Lafuente A, Molina R, Palou J, Castel T, Moral A, Trias M. Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. Br J Cancer 1995;72:324-6
10. Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000;6:498-504
11. Schoof N, von Bonin F, König IR, Mössner R, Krüger U, Reich K, et al. Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: A case-control study. Genes Immun 2009;10: 586-90
12. Pho LN, Leachman SA. Genetics of pigmentation and melanoma predisposition. G Ital Dermatol Venereol 2010;145: 37-45
13. Sondak VK, Chang AE. Melanoma and human leukocyte antigen status: The missing link? Ann Surg Oncol 2002;9: 723-4
14. Yeh I, Bastian BC. Genome-wide associations: Studies for melanoma and nevi. Pigment Cell Melanoma Res 2009;22: 527-8
15. Yang XR, Pfeiffer RM, Wheeler W, Yeager M, Chanock S, Turner MA, et al. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. Int J Cancer 2009;125: 2912-7
16. Udayakumar D, Tsao H. Melanoma genetics: An update on risk-associated genes. Hematol Oncol Clin North Am 2009;23: 415-29
17. Nelson AA, Tsao H. Melanoma and genetics. Clin Dermatol 2009;27:46-52
18. Bishop JN, Harland M, Randerson-Moor J, Bishop DT. Management of familial melanoma. Lancet Oncol 2007;8:46-54
19. Stahl S, Bar-Meir E, Friedman E, Regev E, Orenstein A, Winkler E. Genetics in melanoma. Isr Med Assoc J 2004;6:774-7
20. Sharpless NE, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003;22:3092-8
21. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21
22. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-6
23. Holland EA, Beaton SC, Becker TM, Grulet OM, Peters BA, Rizos H, et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 1995;11:2289-94
24. Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995;11: 405-12
25. Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 1995; 4:1845-52
26. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40
27. Whelan AJ, Bartsch D, Goodfellow PJ. Brief Report: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995;333:975-7
28. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333:970-1
29. Sharpless NE, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003;22:3092-8
30. Tsoa H, Benoit E, Sober AJ, Thiele C, Haluska FG. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res 1998;58:109-13
31. Wagner SN, Wagner C, Briedigkeit L, Goos M. Homozygous deletion of the p16INK4a and the p15INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. Br J Dermatol 1998;138:13-21
32. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23
33. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 1998;95:8292-7
34. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-14
35. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the RB and p53 tumor suppression pathways. Cell 1998;92:725-34
36. Meyle KD, Gulberg P. Genetic risk factors for melanoma. Hum Genet 2009;126:499-510
37. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006;66:9818-28
38. Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, et al. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 2008;47:175-84
39. Molven A, Grimstvedt MB, Steine SJ, Harland M, Avril MF, Hayward NK, et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutations. Genes Chromosomes Cancer 2005;44:10-8
40. Pjanova D, Molven A, Akslen LA, Engele L, Streinerte B, Azarjana K, et al. Identification of a CDK4 R24H mutation-positive melanoma family by analysis of early-onset melanoma patients in Latvia. Melanoma Res 2009;19:119-22
41. Duffy DL, Box NF, Chen W, Palmer JS, Montgomery GW, James MR, et al. Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet 2004;13:447-61
42. Busca R, Ballotti R, Cyclic AMP. a key messenger in the regulation of skin pigmentation. Pigment Cell Res 2000;13: 60-9
43. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996;5: 1663-6
44. Robbins LS, Nadeau JH, Johnson KR, Kelly MA, Roselli-Rehfuss L, Baack E, et al. Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 1993;72:827-34
45. Jackson IJ. Molecular and developmental genetics of mouse coat color. Ann Rev Genet 1994;28:189-217
46. Sturm RA, Duffy DL, Box NF, Chen W, Smit DJ, Brown DL, et al. The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes. Pigment Cell Res 2003;16:266-72
47. Suzuki I, Im S, Tada A, Scott C, Akcali C, Davis MB, et al. Participation of the melanocortin-1 receptor in the UV control of pigmentation. J Investig Dermatol Symp Proc 1999;4:29-34
48. Sturm RA, Teasdale RD, Box NF. Human pigmentation genes: Identification, structure and consequences of polymorphic variation. Gene 2001;277:49-62
49. Frandberg PA, Doufexis M, Kapas S, Chhájlani V. Human pigmentation phenotype: A point mutation generates nonfunctional MSH receptor. Biochem Biophys Res Commun 1998;245:490-2
50. Schioth HB, Sr Phillips, Rudzish R, Birch-Machin MA, Wikberg JE, Rees JL. Loss of function mutations of the human melanocortin 1 receptor are common and are associated with red hair. Biochem Biophys Res Commun 1999;260:488-91
51. Thody AJ, Higgins EM, Wakamatsu K, Ito S, Burchill SA, Marks JM. Pheomelanin as well as eumelanin is present in human epidermis. J Invest Dermatol 1991;97:340-4
52. Napolitano A, Vincensi MR, Di Donato P, Monfrecola G, Prota G. Microanalysis of melanins in mammalian hair by alkaline hydrogen peroxide degradation: Identification of a new structural marker of pheomelanins. J Invest Dermatol 2000; 114:1141-7
53. Robinson S, Dixon S, Augus S, Diffey B, Wakamatsu K, Ito S, et al. Protection against UVR involves MC1R-mediated non-pigmentary and pigmentary mechanisms in vivo. J Invest Dermatol 2010;130:1904-13
54. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11:328-30
55. Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, et al. MC1R variants, melanoma and red hair color phenotype: A meta-analysis. Int J Cancer 2008;122:2753-60
56. Galore-Haskel G, Azizi E, Mohamdi H, Scope A, Chaudru V, Laitman Y, et al. MC1R variant alleles and malignant melanoma risk in Israel. Eur J Cancer 2009;45:2015-22
57. Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: Is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66:176-86
58. Mössner R, Anders N, König I, Krüger U, Schmidt D, Berking C, et al. Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res 2007;298:371-9
59. Chatzinasiou F, Lill CM, Kypreou K, Stefanaki I, Nicolaou V, Spyrou G, et al. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst 2011;103:1227-35
60. Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69: 765-73
61. van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001;69:774-9
62. Fernandez LP, Milne RL, Pita G, Floristan U, Sendagorta E, Feito M, et al. Pigmentation-related genes and their implication in malignant melanoma susceptibility. Exp Dermatol 2009;18:634-42
63. Gudbjartsson DF, Sulem P, Stacey SN, Goldstein AM, Rafnar T, Sigurgeirsson B, et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008;48:886-91
64. Sulem P, Gudbjartsson DF, Stacey SN, Helgason A, Rafnar T, Jakobsdottir M, et al. Two newly identified genetic determinants of pigmentation in Europeans. Nat Genet 2008;40: 835-7
65. Nan H, Kraft P, Hunter DJ, Han J. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 2009;125:909-17
66. Brown KM, Macgregor S, Montgomery GW, Craig DW, Zhao ZZ, Iyadurai K, et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 2008;40:838-40
67. Kanetsky PA, Swoyer J, Panossian S, Holmes R, Guerry D, Rebbeck TR. A polymorphism in the agouti signaling protein gene is associated with human pigmentation. Am J Hum Genet 2002;70:770-5
68. Berson JF, Frank DW, Calvo PA, Bieler BM, Marks MS. A common temperature-sensitive allelic form of human tyrosinase is retained in the endoplasmic reticulum at the nonpermissive temperature. J Biol Chem 2000;275:12281-9
69. Jannot AS, Meziani R, Bertrand G, Gérard B, Descamps V, Archimbaud A, et al. Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma. Eur J Hum Genet 2005;13:913-20
70. Fernandez LP, Milne RL, Pita G, Avilés JA, Lázaro P, Benítez J, et al. SLC45A2: A novel malignant melanoma-associated gene. Hum Mutat 2008;29:1161-7
71. Guedj M, Bourillon A, Combadiéres C, Rodero M, Dieudé P, Descamps V, et al. Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. Hum Mutat 2008;29:1154-60
72. Duffy DL, Zhao ZZ, Sturm RA, Hayward NK, Martin NG, Montgomery GW. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 2010; 130:520-8
73. Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: A systematic review of epidemiological studies. Cancer Causes Control 2001;12: 69-82
74. Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985;102:458-65
75. Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JA, Pastinen T, et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 2009;41:915-9
76. Nan H, Xu M, Zhang J, Zhang M, Kraft P, Qureshi AA, et al. Genome-wide associated study identifies nidogen 1 (NID1) as a susceptibility locus to cutaneous nevi and melanoma risk.Hum Mol Genet 2011;20:2673-9
77. Han J, Kraft P, Nan H, Guo Q, Chen C, Qureshi A, et al. A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet 2008;4:1-11
78. Sulem P, Gudbjartsson DF, Stacey S, Helgason A, Rafnar T, Magnusson KP, et al. Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat Genet 2007;39:1443-52
79. Wang ZQ, Si L, Tang Q, Lin D, Fu Z, Zhang J, et al. Gain-of-function mutation of KIT ligand on melanin synthesis causes familial progressive hyperpigmentation. Am J Hum Genet 2009;84:672-7
80. Howell WM, Turner SJ, Theaker JM, Bateman AC. Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur J Immunogenet 2003;30:409-14
81. Wolfel T, Hauer M, Klehmann E, Brichard V, Ackermann B, Knuth A, et al. Analysis of antigens recognised on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int J Cancer 1993;55:237
82. Gu F, Qureshi AA, Niu T, Kraft P, Guo Q, Hunter DJ, et al. Interleukin and interleukin receptor gene polymorphisms and susceptibility to melanoma. Melanoma Res 2008;18: 330-5
83. Penn I. Depressed immunity and skin cancer. Immunol Today 1984;5:291-3
84. Alonso R, Suarez A, Castro P, Lacave AJ, Gutierrez C. Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res 2005;15:53-60
85. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphisms in the interleukin-10 gene promoter. Eur JImmunogenet 1997;24:1-8
86. Hajeer AH, Lazarus M, Turner D, Mageed RA, Vencovsky J, Sinnott P, et al. IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol 1998;27:142-5
87. Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernández-Caselles T, Frías JF, et al. Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 2002;12:465-9
88. Nikolova PN, Pawelec GP, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN, et al. Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 2007;56:371-9
89. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Bröcker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995;5: 67-8
90. Yue FY, Dummer R, Geersten R, Hofbauer G, Laine E, Manolio S, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997;71:630-7
91. Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, et al. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: An exploratory study. Clin Cancer Res 2005;11:1237-46
92. von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Pequillet I, et al. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J Transl Med 2008;6:1-14
93. Howell WM, Turner SJ, Collins A, Bateman AC, Theaker JM. Influence of TNFa and LTa single nucleotide polymorphisms on susceptibility to and prognosis in cutaneous malignant melanoma in the British population. Eur J Immunogenet 2002;29:17-23
94. Planelles D, Nagore E, Moret A, Botella-Estrada R, Villa E, Guillén C, et al. HLA class II polymorphisms in Spanish melanoma patients: homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor. Br J Dermatol 2006;154: 261-6
95. Lee JE, Loflin PT, Laud PR, Lu M, Reveille JD, Lawlor DA. The human leukocyte antigen TAP2 gene defines the centromeric limit of melanoma susceptibility on chromosome 6p. Tissue Antigens 1996;47:117-21
96. Lee JE, Reveille JD, Ross MI, Platsoucas CD. HLA-DQB1.∗0301 association with increased cutaneous melanoma risk. Int J Cancer 1994;59:510-3
97. Lee JE, Lu M, Mansfield PF, Platsoucas CD, Reveille JD, Ross MI. Malignant melanoma: Relationship of the human leukocyte antigen class II gene DQB1.∗0301 to disease recurrence in American Joint Committee on Cancer stage I or II. Cancer 1996;78:758-63
98. Marincola FM, Shamamian P, Rivoltini L, Salgaller M, Cormier J, Restifo NP, et al. HLA associations in the antitumor response against malignant melanoma. J Immunother 1995;18:242-52
99. Lombardi ML, Mercuro O, Pirozzi G, Ionna F, Lombari V, Mozzillo N, et al. Molecular analysis of HLA DRB1 and DQB1 polymorphism in Italian melanoma patients. J Immunother 1998;21:435-9
100. Lulli P, Grammatico P, Brioli G, Catricalá C, Morellini M, Roccella M, et al. HLA-DR and eDQ alleles in Italian patients with melanoma. Tissue Antigens 1998;51:276-80
101. Kageshita T, Naruse T, Hirai S, Ono T, Horikoshi T, Nakagawa H, et al. Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma. Tissue Antigens 1997;49: 466-70
102. Bateman AC, Turner SJ, Theaker JM, Howell WM. HLA-DQB1.∗0303 and .∗0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antigens 1998;52:67-73
103. Vinceti M, Pellacani G, Casali B, Malagoli C, Nicoli D, Farnetti E, et al. High risk of cutaneous melanoma amongst carriers of the intercellular adhesion molecule-1 R241 allele. Melanoma Res 2006;16:93-6
104. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med 1996;74:13-33
105. Vigano P, Infantino M, Lattuada D, Lauletta R, Ponti E, Somigliana E, et al. Intercellular adhesion molecule-1 (ICAM-1) gene polymorphisms in endometriosis. Mol Hum Reprod 2003;9:47-52
106. Diamond MS, Staunton DE, Marlin SD, Springer TA. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 1991;65:961-71
107. Povey JE, Darakhshan F, Robertson K, Bisset Y, Mekky M, Rees J, et al. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma. Carcinogenesis 2007;28:1087-93
108. Figl A, Scherer D, Nagore E, Bermejo JL, Botella-Estrada R, Gast A, et al. Single-nucleotide polymorphisms in DNA-repair genes and cutaneous melanoma. Mutat Res 2010;702(1):8-16
109. Gu F, Qureshi AA, Kraft P, Guo Q, Hunter DJ, Han J. Polymorphisms in genes involved in DNA repair, cell growth, oxidative stress, and inflammatory response and melanoma risk. Br J Dermatol 2009;161:209-12
110. Figl A, Scherer D, Nagore E, Bermejo JL, Dickes E, Thirumaran RK, et al. Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients. Mutat Res 2009;661: 78-84
111. Firoz EF, Warycha M, Zakrzewski J, Pollens D, Wang G, Shapiro R, et al. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin Cancer Res 2009; 15:2573-80
112. Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, et al. Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer 2009;8:29-32
113. Li C, Liu Z, Wang LE, Strom SS, Lee JE, Gershenwald JE, et al. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis 2006;27: 1894-901
114. Li C, Hu Z, Liu Z, Strom SS, Gershenwald JE, Lee JE, et al. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: A case-control analysis. Cancer Epidemiol Biomarkers Prev 2006;15:2526-32
115. Nan H, Qureshi AA, Prescott J, De Vivo I, Han J. Genetic variants in telomere-maintaining genes and skin cancer risk. Hum Genet 2011;129:247-53
116. Wolf CR, Smith CA, Gough AC, Moss JE, Vallis KA, Howard G, et al. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992;13:1035-8
117. Dolzan V, Rudolf Z, Breskvar K. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis 1995;16:2675-8
118. Strange RC, Ellison T, Ichii-Jones F, Bath J, Hoban P, Lear JT, et al. Cytochrome P450 CYP2D6 genotypes: Association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics 1999;9:269-76
119. Agńdez J. Cytochrome P450 gene polymorphism and cancer. Current Drug Metab 2004;5:211-24
120. Bu H, Rosdahl I, Holmdahl-Källen K, Sun XF, Zhang H. Significance of glutathione S-transferases M1, T1, and P1 polymorphisms in Swedish melanoma patients. Oncol Rep 2007;17:859-64
121. Lusini L, Tripodi SA, Rossi R, Giannerini F, Giustarini D, del Vecchio MT, et al. Altered glutathione antioxidant metabolism during tumor progression in human renal-cell carcinoma. Int J Cancer 2001;91:55-9
122. Baars AJ, Breimer DD. The glutathione S-transferases: Their role in detoxification and toxification of xenobiotics. Ann Biol Clin 1980;38:49-56
123. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6: 733-74
124. Kanetsky PA, Holmes R, Walker A, Najarian D, Swoyer J, Guerry D, et al. Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev 2001;10:509-13
125. Dolzan V, Rudolf Z, Breskvar K. Genetic susceptibility to environmental carcinogenesis in Slovenian melanoma patients. Acta Dermatovenerol Alp Panonica Adriat 2006;15:69-78
126. Santonocito C, Capizzi R, Concolino MM, Lavieri MM, Paradisi A, Gentileschi S, et al. Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism. Br J Dermatol 2007;156:277-82
127. Seifert M, Rech M, Meineke V, Tilgen W, Reichrath J. Differential biological effects of 1,25-dihydroxyvitamin D3 on melanoma cell lines in vitro. J Steroid Biochem Mol Biol 2004;89-90:375-9
128. Calvo MS, Whiting SJ, Barton CN. Vitamin D intake: A global perspective of current status. J Nutr 2005;135:310-6
129. Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009;30:1170-80
130. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A 1988;85:3294-8
131. Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, et al. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol 2007;127: 276-80
132. Halsall JA, Osborne JE, Epstein MP, Pringle JH, Hutchinson PE. The unfavorable effect of the A allele of the vitamin D receptor promoter polymorphism A-1012G has different mechanisms related to susceptibility and outcome of malignant melanoma. Dermatoendocrinol 2009;1:54-7
133. Li C, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, et al. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: A case-control study. Int J Cancer 2008;122:2077-84
134. Gandini S, Raimondi S, Gnagnarella P, Doré JF, Maisonneuve P, Testori A. Vitamin D and skin cancer: A meta-analysis. Eur J Cancer 2009;45:634-41
135. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009;27:5439-44
136. Kefford R, Bishop JN, Tucker M, Bressac-de Paillerets B, Bianchi-Scarrá G, Bergman W, et al. Genetic testing for melanoma. Lancet Oncol 2002;3:653-4
137. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999;17:3245-51
138. Lin J, Hocker TL, Singh M, Tsao H. Genetics of melanoma predisposition. Br J Dermatol 2008;159:286-91.